At Transpharmation Ltd we have established sleep-wake profiling and quantitative EEG (qEEG) assessment in rodents via telemetry to help provide support for the CNS pharmacodynamic activity of novel test compounds. Sleepwake cycles can provide guidance on the CNS stimulant and sedative/hypnotic properties of test compounds relative to comparator references to support the development of novel molecules for a range of therapeutic indications, including sleep disorders. Our expertise in this field at Transpharmation Ltd stems from the original research, conducted previously at GSK, identifying the central effect of the hypothalamic neuropeptide orexin-A on arousal state and reduced sleep. This work was pivotal in guiding the discovery and development of novel orexin receptor antagonists by the pharmaceutical industry for a range of sleep disorders.
Working with Transpharmation Ltd means you can access the same team that made these seminal discoveries. Furthermore this methodology can permit the identification of potential adverse effects of test compounds with respect to a sedative/hypnotic profile to guide therapeutic index predictions and support clinical evaluation in man. qEEG methods allow the identification of CNS pharmacodynamic effects of novel test compounds on spectral power frequency bands, recorded from both surface and depth electrodes, providing a highly-relevant translational biomarker that can be applied to the clinical setting. Importantly qEEG studies can help to guide strategic decision-making around dose-prediction, PK/PD (concentration-effect) relationships as well as site and mechanism of action for a novel CNS penetrant test compound.
|Please contact us to request preclinical Sleep/Wake and EEG full datasets,|